FAST at ASGCT 2026
FAST leadership takes the stage at ASGCT’s Annual Meeting, driving key conversations on gene therapy, clinical collaboration, and patient advocacy shaping Angelman syndrome research.
FAST’s Action Council member, Joe D’Orazio, shares his story with CNBC Cures
When an ER physician’s son was diagnosed with Angelman syndrome, he learned what no medical training could teach: how grief, exhaustion, and love reshape a family—and a career.
Turning Possibility Into Progress: The Rush F.A.S.T. Center for Translational Research Opens in Chicago
FAST and Rush University Medical Center opened a $5 million translational research center, a groundbreaking hub built to accelerate Angelman syndrome trials and train specialists.
Inside INSYNC-AS 2025: Progress, Partnership, and Possibilities for Angelman Syndrome
The 5th Annual INSYNC-AS Meeting brought together top researchers to tackle brain-targeted drug delivery, sharing breakthroughs in blood-brain barrier crossing for Angelman syndrome therapies.
Leading Neurology and Rare Disease Expert Dr. Nick France Joins FAST Board
FAST welcomes Dr. Nick France, a rare disease drug development leader from Alexion, AstraZeneca Rare Disease, to its Board of Directors, bringing two decades of biopharmaceutical and gene therapy expertise.
More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025
FAST attended this year’s ASGCT conference, where Angelman syndrome was featured in 10 scientific presentations and multiple talks—proof the community is helping drive the future of gene and cell therapy.
FAST Speaks at the 2025 MENA Congress for Rare Diseases
FAST representatives Amelia Beatty and Ellen Koekoeckx presented at the MENA Congress for Rare Diseases in Abu Dhabi, highlighting the Angelman syndrome therapeutic pipeline and connecting with regional families and researchers.
FAST Poland Organized the 1st Polish National Angelman Syndrome Conference
FAST Poland hosted its first National Angelman Syndrome Conference for International Angelman Day, drawing 164 registered guests to explore clinical research, epilepsy, safety, and quality of life for AS families.